As of November 14, 2026, Astria Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 23, 2026 (Form 8-K, January 23, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Astria Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Astria Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-23. Every row below is cited to the filing it comes from, and this page adds each new change as Astria Therapeutics, Inc. files it.
Also on the record for Astria Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Stake report, Schedule 13G/A, by Vestal Point Capital, LP | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Glazer Capital, LLC | 6.61% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13D/A, by Perceptive Advisors LLC | — | 5%+ stakes | Source |
| January 28, 2026 | Stake report, Schedule 13D/A, by Magnetar Financial LLC | — | 5%+ stakes | Source |
| December 10, 2025 | Stake report, Schedule 13G, by Glazer Capital, LLC | 5.53% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by ForGrowth III PA B.V. | — | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Vestal Point Capital, LP | 8.8% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 2.2% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 9.1% of the class | 5%+ stakes | Source |
| October 24, 2025 | Stake report, Schedule 13D, by Magnetar Financial LLC | 5.87% of the class | 5%+ stakes | Source |
| October 20, 2025 | Stake report, Schedule 13G/A, by Millennium Management LLC | 0.4% of the class | 5%+ stakes | Source |
| October 16, 2025 | Stake report, Schedule 13D/A, by Perceptive Advisors LLC | 11.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Astria Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Astria Therapeutics, Inc. and the records around it.
Astria Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Feb 2026
Companies that share a holder
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Aura Biosciences, Inc. (Oct 2026), Vor Biopharma Inc. (Dec 2025), Crescent Biopharma, Inc. (Dec 2025)
- Fairmount Funds Management LLC also filed stake reports on 14 other companies: Mentari Therapeutics, Inc. (Nov 2026), Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
Watch Astria Therapeutics, Inc.
Get an email when Astria Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Astria Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Astria Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Astria Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-01-23 | Reported | not named in the filing | 8-K, 2026-01-23 |
New leaders reset buying decisions — get the Full Report on Astria Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Astria Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Astria Therapeutics, Inc.Every change, in the filing's words
Reported
As a result of the Merger and pursuant to the terms of the Merger Agreement, effective as of the Effective Time, (i) each of Kenneth Bate, Sunil Agarwal, M.D., Joanne T. Beck, Ph.D., Fred Callori, Hugh M. Cole, Michael D. Kishbauch, Gregg Lapointe, Jill C. Milne, Ph.D., and Jonathan Violin, Ph.D., resigned from their respective positions as directors of Astria and from all committees of the board of directors of Astria on which such directors served, and (ii) each of Jill C. Milne, Ph.D., Noah Clauser, CPA, Andrew A. Komjathy, Chris Morabito, M.D., Ben Harshbarger, J.D., and Andrea Matthews re
- From and after the Effective Time and pursuant to the terms of the Merger Agreement, (i) Babar Ghias and Alane Barnes (the directors of Merger Sub immediately prior to the Effective Time) have become the directors of Astria and (ii) the following individuals became the executive officers of Astria: Babar Ghias as the President and Alane Barnes as the Secretary, in each of the foregoing cases until successors are duly elected or appointed and qualified in accordance with Astria's certificate of incorporation and bylaws and applicable law.
Tools for this story
Each opens in a new tab, filled in for Astria Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
